Prelude Capital Management
REVBW icon

Prelude Capital Management’s Revelation Biosciences Warrant REVBW Stock Holding History

Prelude Capital Management’s Portfolio REVBW Stock Details REVBW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,755
Closed -$11K – 2205
2021
Q3 		$11K Buy
17,755
+722
+4% +$438 ﹤0.01% 1623
2021
Q2 		$11K Buy
+17,033
New +$10.2K ﹤0.01% 1592

Other funds holding REVBW

Owl Creek Asset Management
Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return
Linden Advisors
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
CVI Holdings
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Yakira Capital Management
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
Ionic Capital Management
Ionic Capital Management New York $690M AUM 70.34% 1-Year Est. Return
Rivernorth Capital Management
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
Empery Asset Management
Empery Asset Management New York $86.5M AUM
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Capstone Investment Advisors
Capstone Investment Advisors New York $54B AUM 23.5% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Prelude Capital Management's REVBW Position: Q4 2021 in Review

Prelude Capital Management sold out of Revelation Biosciences Warrant (REVBW) in Q4 2021, closing a stake of 17,755 shares — an estimated $11K sold.

Prelude Capital Management first reported a position in REVBW in Q2 2021 and held it in 2 quarters. The position peaked at $11K in Q3 2021. 20 funds tracked by Wall St. Rank hold REVBW as of Q4 2021.

  • Prelude Capital Management reported no remaining Revelation Biosciences Warrant position as of Q4 2021 after selling out during the quarter.
  • Prelude Capital Management sold 17,755 Revelation Biosciences Warrant shares in Q4 2021, an estimated $11K.
  • Prelude Capital Management first reported a position in Revelation Biosciences Warrant in Q2 2021 and held it in 2 quarters.
  • Prelude Capital Management's Revelation Biosciences Warrant position peaked at $11K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q4 2021.

Based on Prelude Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.